26.07.2013 Views

Untitled - D Ank Unlimited

Untitled - D Ank Unlimited

Untitled - D Ank Unlimited

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Raji cell assay for CIC 611 rapamycin<br />

After combination of Raji cells with a serum sample, the<br />

immune complex is bound and quantified using radiolabeled<br />

F(ab′) 2 fragments of antibodies against IgG.<br />

Raji cell assay for CIC<br />

One of the least analytically sensitive and least diagnostically<br />

specific assays for circulating immune complexes<br />

(CICs). Positive results may signify the presence of lymphocyte<br />

antibodies, particularly in systemic lupus erythematosus<br />

(SLE). Patients with systemic necrotizing vasculitis may<br />

appear positive in Raji assays for CICs. This assay has also<br />

been used to monitor sarcoidosis patients.<br />

Ramon, Gaston (1886–1963)<br />

French immunologist who perfected the flocculation assay<br />

for diphtheria toxin.<br />

Ramon test (historical)<br />

A rough method for assaying the activity of a preparation of<br />

diphtheria (or tetanus) toxin. Varying quantities of antitoxin<br />

are combined with a constant quantity of toxin in vitro. The<br />

tubes are placed in a 44 to 46°C water bath and observed<br />

often. The test is read by noting the tube in which flocculation<br />

occurs first. This is the point of equivalence where<br />

antitoxin has neutralized the homologous toxin. This assay<br />

is based on the antigenicity of the toxin with which the<br />

antitoxin combines, in contrast to toxicity. Thus, it measures<br />

combining power and provides an indirect idea of toxicity<br />

only insofar as toxicity and antigenicity are positively correlated.<br />

Because they are not always closely correlated, this<br />

method is less reliable than the in vivo technique of Ehrlich<br />

that measures the actual toxic effect of the toxin and the<br />

ability of the antitoxin to combat it. The Ramon test measures<br />

toxin in L f (flocculating) units. An L f unit is defined as<br />

the amount of toxin that flocculates most rapidly with one<br />

unit of antitoxin. The L f value, in contrast to other L values<br />

described, must be calculated. To determine the L f value for<br />

a toxin, the following formula is used.<br />

L f /mL toxin = ([antitoxin units/mL] × [mL antitoxin]) ÷ (mL of toxin)<br />

Thus, the L f content of a toxin may be determined if the following<br />

values are known: (1) antitoxin units per milliliter of<br />

antitoxin, (2) milliliter of antitoxin required for most rapid<br />

flocculation with toxin, and (3) milliliter of toxin employed.<br />

Although the Ramon flocculation test was classically used to<br />

determine the L f value of toxin, it may be carried out in reverse<br />

to assay the antitoxin units in each milliliter of antitoxin not<br />

previously standardized. The same formula is applicable:<br />

L f /mL toxin = ([antitoxin units/mL] × [mL antitoxin]) ÷ (mL toxin)<br />

Antitoxin units/mL = ([L f /mL toxin] × [mL toxin]) ÷ (mL antitoxin)<br />

Varying quantities of toxin of known L f value are combined<br />

with a constant amount of antiserum. The tube in which<br />

flocculation first occurs is the point of equivalence; therefore,<br />

the amount of toxin in a milliliter is substituted into<br />

the formula together with the known values that include the<br />

L f per milliliter of toxin and the number of milliliters of<br />

antitoxin held constant. By simple arithmetic, the antitoxin<br />

units per milliliter may then be calculated. In this quantitative<br />

precipitin test, antibody dilutions are varied and antigen<br />

dilutions remain the same. The first tube where precipitation<br />

occurs is considered the end point.<br />

RANA (rheumatoid arthritis-associated nuclear antigen)<br />

An antigen of Epstein–Barr virus (EBV)-immortalized<br />

lymphoid cell lines that reacts with sera from patients with<br />

rheumatoid arthritis.<br />

RANA (rheumatoid arthritis-associated nuclear antigen)<br />

autoantibodies<br />

Patients with rheumatoid arthritis (RA) develop antibodies<br />

to Epstein–Barr virus (EBV)-related antigens that include<br />

viral capsid antigen, early antigen, EBV nuclear antigen,<br />

and rheumatoid arthritis nuclear antigen. RANA antibodies<br />

are present in approximately 60% of RA patients, as<br />

revealed by incomplete Freund’s adjuvant (IFA) or enzyme<br />

immunoassay (EIA) techniques using synthetic peptide<br />

P62, which is the equivalent of the principal epitope of<br />

RANA. The clinical significance of RANA antibodies<br />

remains to be determined.<br />

random breeding<br />

The mating of members of a population at random. The<br />

genetic diversity arising from random breeding depends<br />

on the size of the population. If it is large, genetic diversity<br />

will be maintained. If it is small, genetic uniformity will<br />

result in spite of random breeding.<br />

RANTES<br />

An 8-kDA protein comprised of 68-amino acid residues.<br />

It belongs to the platelet factor-4 (PF-4) superfamily of<br />

chemoattractant proteins. RANTES chemoattracts blood<br />

monocytes and CD4 + /CD45RO + T cells in vitro and is useful<br />

in research on inflammation. A chemokine of the β (CC)<br />

family, RANTES was first identified by molecular cloning as<br />

a transcript expressed in T cells but not B cells. It is the only<br />

β chemokine in platelets and demonstrates powerful chemotactic<br />

and activating properties for basophils, eosinophils, and<br />

natural killer (NK) cells. It has a human immunodeficiency<br />

virus (HIV)-suppressive effect and acts synergistically with<br />

macrophage inflammatory peptide 1α (MIP-1α) and MIP-1β<br />

in the suppression of HIV. Tissue sources include T lymphocytes,<br />

monocytes, epithelial cells, mesangial cells, platelets,<br />

and eosinophils, among other cell types. Monocytes, T lymphocytes,<br />

basophils, eosinophils, natural killer (NK) cells,<br />

dendritic cells, and mast cells are targets.<br />

MeO<br />

MeO<br />

O<br />

H<br />

O<br />

OH<br />

O<br />

OH<br />

O<br />

rapamycin<br />

Refer to sirolimus. To achieve clinical immunosuppression,<br />

rapamycin is effective at one eighth the concentration required<br />

for FK506 and at 1% of levels required for cyclosporine.<br />

O<br />

H<br />

N<br />

O<br />

Structure of rapamycin.<br />

OMe<br />

OH<br />

R

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!